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EDITORIAL
Adults  with  cystic  ﬁbrosis  in Portugal:  A ﬁrst  step
towards improvement
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RThe  last  two  decades  have  seen  improving  survival  in
patients  with  cystic  ﬁbrosis  (CF)  with  more  patients  liv-
ing  into  adulthood.1 The  improvement  in  survival  can  be
attributed  to  a  number  of  factors  including  new  medica-
tions,  greater  use  of  antibiotics,  better  nutrition,  and  the
development  of  specialized  centers  where  teams  of  care-
givers  provide  expert  evaluation  and  guidance.  Yet  despite
such  gains,  our  patients  still  die  too  young  and  their  treat-
ments  come  with  considerable  burden,  so  there  remains
great  opportunity  for  further  improvements.  While  we  antic-
ipate  the  development  of  newer  therapeutic  options,  we  can
still  strive  to  be  even  better  with  the  tools  we  have  now.
Quality  improvement  (QI)  is  a  systematic  and  continuous
process  leading  to  measurable  improvement  in  the  health
status  of  our  patients.  A  key  aspect  of  QI  is  measurement,
meaning  there  must  be  access  to  data  in  order  to  under-
stand  the  current  state  of  affairs,  to  identify  opportunities
for  improvement,  and  to  assess  the  impact  of  the  interven-
tions.  In  this  issue  of  the  Portuguese  Journal  of  Pulmonology,
Silva  and  colleagues  provide  a  glimpse  into  the  current  sta-
tus  of  the  adult  cystic  ﬁbrosis  population  in  Portugal.2 The
analysis  describes  the  89  adult  patients  who  receive  their
care  at  three  CF  centers.  The  temptation  is  always  to  com-
pare  these  observations  to  others,  but  it  is  imperative  to
avoid  interpreting  them  in  a  manner  in  which  we  take  credit
for  some  and  cast  blame  for  others.  Rather,  the  point  is  that
it  is  merely  a  portrait  of  the  current  state  upon  which  one
can  develop  plans  for  improvement.
Comparison  to  other  registries,  such  as  the  US  CF  Patient
Registry,1 is  not  always  so  easy  since  the  latter  reports  data
inclusive  of  all  patients,  not  merely  the  adults.  For  example,
in  this  report  the  median  age  of  diagnosis  is  reported  as  13
years  in  Portugal,  whereas  in  the  US  the  Registry  reports  it  as
3.7  years.  Presumably  the  median  age  of  diagnosis  in  Portu-
gal,  were  we  to  include  all  patients,  is  far  younger,  but  it  is
notable  that  in  Portugal  there  is  a  larger  proportion  (nearly
40%)  of  patient  that  are  not  diagnosed  until  adulthood.  In  the
US,  for  example,  <5%  of  patients  are  diagnosed  in  adulthood
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 previous  report  have  suggested  that  late  diagnosis  may
eﬁne  a  population  of  long-term  survivors,3 but  this  cohort
valuated  only  those  patients  >40  years  of  age  and  with  a
edian  age  of  diagnosis  of  48.5  years,  so  it  is  not  the  best
omparison.  Of  note,  the  median  age  of  diagnosis  in  the  US
s  slowly  creeping  upward  (3.1  years  to  3.7  years  in  the  last
ecade)  but  this  is  in  an  era  of  newborn  screening  where  the
iagnosis  would  be  made  in  the  ﬁrst  few  months  of  life.  This
uggests  that  there  is  greater  identiﬁcation  of  older  patients
ith  milder  manifestations;  that  is,  that  clinicians  are  now
ncluding  CF  in  their  differential  diagnosis  of  patients
ith  respiratory  or  other  CF-related  symptoms.  Another
otential  explanation  for  the  later  diagnosis  in  Portugal  is  a
arger  percentage  of  milder  CF  mutations,  demonstrated  by
he  lower  proportion  of  patients  that  are  homozygous  for
508del  (nearly  50%  in  the  US).  However  it  is  also  possible
hat  those  patients  with  more  severe  mutations  have  a
educed  survival  and  that  this  mutation  analysis  in  the
dults  is  not  representative  of  the  Portuguese  pediatric  CF
opulation.
There  are  many  more  questions  that  could  be  explored
n  this  population  and  establishing  the  database  and  making
t  transparent  can  now  allow  for  generation  of  hypotheses
eading  to  QI  projects.  A  clear  opportunity  acknowledged
y  the  authors  is  earlier  diagnosis.  Implementation  of
 newborn  screening  program  would  allow  for  earlier
reatment  interventions.4 This  is  but  one  example,  but
hat  is  how  it  starts.  We  applaud  the  authors  and  the
ortuguese  CF  community  for  presenting  their  data  and
ook  forward  to  future  revelations  demonstrating  clinical
mprovements.
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